دورية أكاديمية
أعرض في EDS

Towards personalised dosimetry in patients with liver malignancy treated with 90 Y-SIRT using in vivo-driven radiobiological parameters.

التفاصيل البيبلوغرافية
العنوان: Towards personalised dosimetry in patients with liver malignancy treated with 90 Y-SIRT using in vivo-driven radiobiological parameters.
المؤلفون: Gholami YH; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. yaser.gholami@sydney.edu.au.; Sydney Vital Translational Cancer Research Centre, University of Sydney, Sydney, Australia. yaser.gholami@sydney.edu.au.; Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia. yaser.gholami@sydney.edu.au., Willowson KP; Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia., Bailey DL; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. dale.bailey@sydney.edu.au.; Sydney Vital Translational Cancer Research Centre, University of Sydney, Sydney, Australia. dale.bailey@sydney.edu.au.; Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia. dale.bailey@sydney.edu.au.
المصدر: EJNMMI physics [EJNMMI Phys] 2022 Jul 30; Vol. 9 (1), pp. 49. Date of Electronic Publication: 2022 Jul 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag, GmbH Country of Publication: Germany NLM ID: 101658952 Publication Model: Electronic Cited Medium: Print ISSN: 2197-7364 (Print) Linking ISSN: 21977364 NLM ISO Abbreviation: EJNMMI Phys Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Heidelberg, Germany : Springer-Verlag, GmbH, [2014]-
مستخلص: Background: The prediction of response is one of the major challenges in radiation-based therapies. Although the selection of accurate linear-quadratic model parameters is essential for the estimation of radiation response and treatment outcome, there is a limited knowledge about these radiobiological parameters for liver tumours using radionuclide treatments.
Methods: The "clinical radiobiological" parameters ([Formula: see text], [Formula: see text], [Formula: see text], [Formula: see text]) for twenty-five patients were derived using the generalised linear-quadratic model, the diagnostic ([ 18 F] FDG PET/CT) and therapeutic ([ 90 Y]-SIR-Spheres PET/CT) images to compute the biological effective dose and tumour control probability (TCP) for each patient.
Results: It was estimated that the values for [Formula: see text] and [Formula: see text] parameters range in ≈ 0.001-1 Gy -1 and ≈ 1-49 Gy, respectively. We have demonstrated that the time factors, [Formula: see text], [Formula: see text] and [Formula: see text] are the key parameters when evaluating liver malignancy lesional response to [ 90 Y]SIR-Spheres treatment. Patients with cholangiocarcinoma have been shown to have the longest average [Formula: see text] (≈ 236 ± 67 d), highest TCP (≈ 53 ± 17%) and total liver lesion glycolysis response ([Formula: see text] ≈ 64%), while patients with metastatic colorectal cancer tumours have the shortest average [Formula: see text] (≈ 129 ± 19 d), lowest TCP (≈ 28 ± 13%) and [Formula: see text] ≈ 8%, respectively.
Conclusions: Tumours with shorter [Formula: see text] have shown a shorter [Formula: see text] and thus poorer TCP and [Formula: see text]. Therefore, these results suggest for such tumours the [ 90 Y]SIR-Spheres will be only effective at higher initial dose rate (e.g.  > 50 Gy/day).
(© 2022. The Author(s).)
References: Australas Phys Eng Sci Med. 2001 Sep;24(3):132-46. (PMID: 11764395)
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):207-218. (PMID: 30684661)
Clin Nucl Med. 2011 Dec;36(12):e186-7. (PMID: 22064104)
J Clin Oncol. 2018 Jul 1;36(19):1913-1921. (PMID: 29498924)
Med Phys. 2008 Mar;35(3):1123-34. (PMID: 18404947)
Br J Radiol. 1969 Jun;42(498):427-31. (PMID: 5810854)
J Appl Clin Med Phys. 2018 Sep;19(5):435-443. (PMID: 29962026)
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1202-22. (PMID: 25967868)
Radiat Oncol. 2018 May 16;13(1):96. (PMID: 29769103)
Medicine (Baltimore). 2015 Jun;94(23):e945. (PMID: 26061323)
Rep Pract Oncol Radiother. 2015 Sep-Oct;20(5):328-39. (PMID: 26549990)
J Hepatol. 2019 Dec;71(6):1164-1174. (PMID: 31421157)
Dig Surg. 1998;15(1):21-4. (PMID: 9845558)
Phys Med Biol. 2018 Dec 19;64(1):01TR01. (PMID: 30523903)
J Clin Oncol. 2010 Aug 10;28(23):3687-94. (PMID: 20567019)
BJS Open. 2020 Sep 30;:. (PMID: 32996713)
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):900-7. (PMID: 18262101)
Ann Biomed Eng. 2020 May;48(5):1499-1510. (PMID: 32006268)
Phys Med Biol. 2015 Mar 7;60(5):1945-64. (PMID: 25668639)
Lancet Oncol. 2017 Dec;18(12):1624-1636. (PMID: 29107679)
N Engl J Med. 2012 Mar 8;366(10):883-892. (PMID: 22397650)
J Gastrointest Surg. 2013 Apr;17(4):739-47. (PMID: 23292461)
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):654-61. (PMID: 17467926)
Int J Radiat Biol. 1997 Oct;72(4):351-74. (PMID: 9343102)
J Radiat Res. 2014 Jan 1;55(1):175-82. (PMID: 23869025)
Onco Targets Ther. 2019 Jun 07;12:4489-4498. (PMID: 31239717)
Am J Roentgenol Radium Ther Nucl Med. 1956 Nov;76(5):988-1000. (PMID: 13362715)
Biomark Cancer. 2016 Sep 20;8(Suppl 2):61-9. (PMID: 27679534)
Cancer. 1961 Nov-Dec;14:1272-94. (PMID: 13909709)
Semin Radiat Oncol. 2008 Oct;18(4):240-3. (PMID: 18725110)
J Vasc Interv Radiol. 2018 Aug;29(8):1101-1108. (PMID: 30042074)
Semin Radiat Oncol. 2008 Oct;18(4):234-9. (PMID: 18725109)
Immunol Rev. 1995 Jun;145:91-122. (PMID: 7590832)
J Natl Cancer Inst. 2018 Apr 1;110(4):329-340. (PMID: 29126306)
Can J Gastroenterol Hepatol. 2020 Nov 23;2020:5104082. (PMID: 33299824)
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1570-1584. (PMID: 33433699)
EJNMMI Phys. 2018 Sep 3;5(1):18. (PMID: 30175390)
J Hepatol. 2005 Aug;43(2):310-6. (PMID: 15970351)
Clin Oncol (R Coll Radiol). 2002 Oct;14(5):382-93. (PMID: 12555877)
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2270-2279. (PMID: 31324943)
J Surg Oncol. 1996 Jan;61(1):68-83. (PMID: 8544465)
Cancer Treat Rep. 1985 Jun;69(6):615-32. (PMID: 3893692)
Phys Med Biol. 2003 Sep 7;48(17):2753-65. (PMID: 14516099)
EJNMMI Res. 2017 Dec;7(1):46. (PMID: 28536968)
Clin Oncol (R Coll Radiol). 1996;8(5):297-307. (PMID: 8934049)
Acta Oncol. 1988;27(2):83-8. (PMID: 3291903)
Med Phys. 2012 Jan;39(1):224-30. (PMID: 22225291)
Phys Med. 2020 Dec;80:317-326. (PMID: 33248338)
Cancer Res. 1985 May;45(5):2145-53. (PMID: 3986767)
Semin Oncol. 2011 Feb;38(1):55-69. (PMID: 21362516)
Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1718-1738. (PMID: 26112387)
Sci Transl Med. 2010 Jul 7;2(39):39ra48. (PMID: 20610850)
فهرسة مساهمة: Keywords: 90Y; Dose; Radioembolisation; Response; SIRT
تواريخ الأحداث: Date Created: 20220730 Latest Revision: 20220802
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9339072
DOI: 10.1186/s40658-022-00479-7
PMID: 35907097
قاعدة البيانات: MEDLINE
الوصف
تدمد:2197-7364
DOI:10.1186/s40658-022-00479-7